Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620680 | 0.85 | KDM4E (0.62) | KDM4ESMN1; SMN2NR1H2ACHEADRA2B | |
| SCHEMBL13495620 | 0.85 | SMN1; SMN2 (0.67) | KDM4ESMN1; SMN2NR1H2ACHEADRA2B | |
| SCHEMBL2924537 | 0.83 | KDM4E (0.70) | KDM4ESMN1; SMN2ACHELMNACHRM2 | |
| Hydrochloric Acid SCHEMBL15568255 | 0.82 | KDM4E (0.68) | KDM4ESMN1; SMN2ACHELMNACHRM2 | |
| Hydrochloric Acid SCHEMBL1238937 | 0.82 | KDM4E (0.68) | KDM4ESMN1; SMN2ACHELMNACHRM2 | |
| SCHEMBL15542251 | 0.81 | NR1H2 (0.67) | KDM4ESMN1; SMN2NR1H2ACHELMNA | |
| SCHEMBL626141 | 0.81 | OPRM1 (0.49) | KDM4ESMN1; SMN2LMNACHRM2CYP1A2 | |
| SCHEMBL922214 | 0.81 | CYP2A13 (0.61) | KDM4ESMN1; SMN2NR1H2ACHEALDH1A1 | |
| SCHEMBL20971765 | 0.81 | CXCR3 (0.57) | KDM4ESMN1; SMN2SOS1CXCR3 | |
| SCHEMBL30309475 | 0.81 | NR1H2 (0.51) | KDM4ESMN1; SMN2NR1H2ACHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-2658543-B1 | PYRUVATE KINASE M2 (PKM2) ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| CN-1933839-A | Compounds and methods of use | AMGEN INC (US) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KDM4E 1662/4885SMN1; SMN2 882/4885NR1H2 2170/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KDM4E 1409/4885SMN1; SMN2 835/4885NR1H2 3271/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | KDM4E 1662/4885SMN1; SMN2 882/4885NR1H2 2170/4885 |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | KDM4E 2929/4885SMN1; SMN2 4848/4885NR1H2 1693/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | KDM4E 1662/4885SMN1; SMN2 882/4885NR1H2 2170/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | KDM4E 1843/4885SMN1; SMN2 609/4885NR1H2 3588/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KDM4E 1645/4885SMN1; SMN2 986/4885NR1H2 2183/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | KDM4E 1645/4885SMN1; SMN2 986/4885NR1H2 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.